RET and non-small cell lung carcinoma: In conclusion, this case describes real-world experiences of using RET-TKIs in patients with RET fusion-positive NSCLC, underscoring the importance of adequate baseline assessment and ongoing monitoring of immune function, infection biomarkers, and chest CT scans to inform future clinical practice.